2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary

Calkins, Hugh; Hindricks, Gerhard; Cappato, Riccardo; Kim, Young Hoon; Saad, Eduardo; Aguinaga, Luis; Akar, Joseph G.; Badhwar, Vinay; Brugada, Josép; Camm, John; Chen, Peng Sheng; Chen, Shih Ann; Chung, Mina K.; Nielsen, Jens Cosedis; Curtis, Anne B.; Davies, D. Wyn; Day, John D.; d’Ávila, André; Groot, Natasja M.S. de; Biase, Luigi Di; Duytschaever, Mattias; Edgerton, James R.; Ellenbogen, Kenneth A.; Ellinor, Patrick T.; Ernst, Sabine; Fenelon, Guilherme; Gerstenfeld, Edward P.; Haines, David E.; Haı̈ssaguerre, Michel; Helm, Robert H.; Hylek, Elaine M.; Jackman, Warren M.; Jalife, José; Kalman, Jonathan M.; Kautzner, Josef; Kottkamp, Hans; Kuck, Karl Heinz; Kumagai, Koji; Lee, Richard; Lewalter, Thorsten; Lindsay, Bruce D.; Macle, Laurent; Mansour, Moussa; Marchlinski, Francis E.; Michaud, Gregory F.; Nakagawa, Hiroshi; Natale, Andrea; Nattel, Stanley; Okumura, Ken; Packer, Douglas L.; Pokushalov, Evgeny; Reynolds, Matthew R.; Sanders, Prashanthan; Scanavacca, Maurício; Schilling, Richard J.; Tondo, Claudio; Tsao, Hsuan Ming; Verma, Atul; Wilber, David J.; Yamane, Teiichi

doi:10.1007/s10840-017-0277-z

Cited by 161 publications

(203 citation statements)

References 581 publications

Supporting

Mentioning

197

Contrasting

Order By: Relevance

“…1 Advances in electro-physiological technology and increased operator experience over the last decade have permitted catheter ablation to emerge as standard therapy for symptomatic, drug-refractory AF. 2,3 However, obtaining long-term PVs electrical isolation remains challenging with just a single procedure. 4 A lot of work has been made to develop ablation catheter with the intent of increasing long-term efficacy and safety of AF ablation.…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of the ThermoCool SmartTouch SurroundFlow catheter for atrial fibrillation ablation: A meta‐analysis

Chen

Gao

Liu

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Background The ThermoCool Smarttouch Surroundflow catheter (STSFc) is an advanced catheter, which integrating contact force sensing and surroundflow technology. However, comparative data between STSFc and contact force sensing catheter (Thermocool SmartTouch catheter [STc]) are limited. Hypothesis We thought that STSFc might bring more clinical benefits. The aim of this meta‐analysis was to compare the safety and efficiency between the STSFc and the STc for treatment of atrial fibrillation (AF). Methods The Medline, PubMed, Embase, and Cochrane Library databases were searched for studies comparing STSFc and STc. Results Four trials involving 727 patients were included in the study. Pool‐analyses demonstrated that, as compared STc ablation, STSFc ablation was more beneficial in terms of procedural times (standard mean difference [SMD]: −0.22; 95% confidence interval [CI], −0.37 to −0.07, P = .005) and irrigation fluid volume (SMD: −1.94; 95% CI, −2.65 to −1.22, P < .0001). There was no significant difference between STSFc and STc (risk ratio [RR]: 1.02; 95% CI: 0.86 to 1.21, P = .79) for free from AF. Evidence of complications were low and similar for both groups (RR: 0.83; 95% CI: 0.19‐3.55, P = .80). Additionally, patients administered STSFc ablation tended to have shorter fluoroscopic times (SMD: −0.20; 95% CI, −0.63‐0.23, P = .21). Conclusions STSFc ablation was associated with reducing procedural times and irrigation fluid volume. Further, STSFc ablation tended to shorten fluoroscopic times. Therefore, STSFc ablation would be a better choice for AF patients especially in patients with heart failure.

show abstract

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of the ThermoCool SmartTouch SurroundFlow catheter for atrial fibrillation ablation: A meta‐analysis

Chen

Gao

Liu

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…30 Although up to 50% of patients suffer an early recurrence after PVI within 3 months after the procedure, up to half of patients with early recurrence remain AF-free in a long-term follow-up. 33 Late recurrence more than 3 months after ablation occurs in 25%-40% of cases depending on the population of AF patients and the ratio of persistent to paroxysmal AF. 33 Overall, the efficacy of PVI is significantly higher than chronic treatment with AADs.…”

Section: Investigators Of Arrhythmia and Mortality On Dofetilide In Cmentioning

confidence: 99%

“…33 Late recurrence more than 3 months after ablation occurs in 25%-40% of cases depending on the population of AF patients and the ratio of persistent to paroxysmal AF. 33 Overall, the efficacy of PVI is significantly higher than chronic treatment with AADs. 27,33,36…”

Section: Investigators Of Arrhythmia and Mortality On Dofetilide In Cmentioning

confidence: 99%

Catheter ablation of atrial fibrillation—A key role in heart failure therapy?

Paiva

Fischer

Brachmann

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Atrial fibrillation (AF) and heart failure (HF) are epidemic cardiac diseases and are often detected in the same patient. Recent evidence suggests that this is not a mere coincidence but that the strategy of AF treatment may impact HF development. This review comprehensively summarizes current trial data on rhythm and rate control strategies in atrial fibrillation with a special focus on catheter ablation of AF in HF patients. For a long time , rate and rhythm control strategies for AF have been regarded as equal regarding long term mortality. Decision making has been based on the symptoms of patients. Current trials, however, show that the treatment strategy of AF and its effectiveness may significantly impact survival of HF patients. The benefits of rhythm control in HF patients may have been masked by side effects of antiarrhythmic drugs. If rhythm control, however, is achieved by catheter ablation, a reduction of HF related mortality can be observed. As catheter ablation of AF may reduce mortality in HF patients, AF ablation should be preferred over medical treatment in HF patients. In general, HF patients may profit most from rigorous AF treatment.

show abstract

“…Anticoagulation in the setting of AF ablations remains a difficult problem. On one hand, an increased risk of thromboembolic complications exists in these patients, on the other there is a substantial risk of bleeding during the procedure [119,120]. The last NOAC dose should be administered 12 hours before AF ablation, especially if transseptal puncture is to be performed without periprocedural imaging.…”

Section: High Bleeding Riskmentioning

confidence: 99%

Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

et al. 2018

View full text Add to dashboard Cite

show abstract

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary

Cited by 161 publications

References 581 publications

Safety and efficacy of the ThermoCool SmartTouch SurroundFlow catheter for atrial fibrillation ablation: A meta‐analysis

Safety and efficacy of the ThermoCool SmartTouch SurroundFlow catheter for atrial fibrillation ablation: A meta‐analysis

Catheter ablation of atrial fibrillation—A key role in heart failure therapy?

Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

Contact Info

Product

Resources

About